Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Operating Expenses: 2021-2025

Historic Operating Expenses for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $156.8 million.

  • Kiniksa Pharmaceuticals International's Operating Expenses rose 28.69% to $156.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $559.8 million, marking a year-over-year increase of 36.43%. This contributed to the annual value of $468.9 million for FY2024, which is 58.69% up from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported Operating Expenses of $156.8 million as of Q3 2025, which was up 14.78% from $136.6 million recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's 5-year Operating Expenses high stood at $156.8 million for Q3 2025, and its period low was $42.8 million during Q3 2021.
  • Over the past 3 years, Kiniksa Pharmaceuticals International's median Operating Expenses value was $108.7 million (recorded in 2024), while the average stood at $107.5 million.
  • Per our database at Business Quant, Kiniksa Pharmaceuticals International's Operating Expenses decreased by 3.98% in 2022 and then skyrocketed by 70.24% in 2024.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Operating Expenses (Quarterly) stood at $54.9 million in 2021, then rose by 1.75% to $55.8 million in 2022, then spiked by 49.21% to $83.3 million in 2023, then skyrocketed by 70.24% to $141.8 million in 2024, then rose by 28.69% to $156.8 million in 2025.
  • Its Operating Expenses stands at $156.8 million for Q3 2025, versus $136.6 million for Q2 2025 and $124.5 million for Q1 2025.